Current clinical applications of botulinum toxin

Current Pharmaceutical Design

Volumn 15, Issue 31, 2009, Pages 3671-3680

  Truong, Daniel D ^a   Stenner, Andrea ^b   Reichel, Gerhard ^b  

^a Parkinson's and Movement Disorder Institute   (United States)

^b Paracelsus Clinic   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BOTULINUM TOXIN; BOTULINUM TOXIN A; BOTULINUM TOXIN B; PLACEBO;

ACETYLCHOLINE RELEASE; ANUS FISSURE; AXIAL DYSTONIA; BLEPHAROSPASM; BRUXISM; CALF SPASTICITY; CENTRAL NERVOUS SYSTEM; CERVICAL DYSTONIA; CHOLINERGIC SYNAPSE; CLINICAL TRIAL; CONSTIPATION; DETRUSOR DYSSYNERGIA; DIPLOPIA; DRUG ACTIVITY; DRUG COST; DRUG EFFICACY; DRUG FORMULATION; DRUG PROTEIN BINDING; DRUG RELEASE; DRUG SAFETY; DRUG TOLERABILITY; DRY EYE; DYSPHAGIA; ECHOGRAPHY; ELECTROSTIMULATION; EQUINIUS GAIT; ESOPHAGUS ACHALASIA; EYE DISEASE; FOCAL DYSTONIA; GASTROINTESTINAL DISEASE; GILLES DE LA TOURETTE SYNDROME; HUMAN; HYPERHIDROSIS; HYPERREFLEXIVE BLADDER; LACRIMATION DISORDER; LAGOPHTHALMOS; MOTOR SYSTEM; NECK WEAKNESS; NEUROGENIC DETRUSOR OVERACTIVITY; NEUROMUSCULAR SYNAPSE; OROMANDIBULAR DYSTONIA; OVERACTIVE BLADDER; PAIN; PARALYSIS; PARKINSONISM; PATIENT SATISFACTION; POINT TOUCH; PRIORITY JOURNAL; PROCTOLOGY; PTOSIS; QUALITY OF LIFE; REVIEW; ROSS SYNDROME; SPASMODIC DYSPHONIA; SPASTICITY; STRABISMUS; SWEAT GLAND DISEASE; TARDIVE DYSKINESIA; TARDIVE DYSTONIA; TOUCH; TREATMENT INDICATION; TREATMENT RESPONSE; TREMOR; URINARY TRACT DISEASE; VAGINISM; WEAKNESS; WRITER'S CRAMP; XEROSTOMIA;

ACETYLCHOLINE; ANIMALS; ANTI-DYSKINESIA AGENTS; BOTULINUM TOXINS; CLINICAL TRIALS AS TOPIC; HUMANS; NEUROMUSCULAR JUNCTION; SYNAPSES;

EID: 70449584743     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/138161209789271843     Document Type: Review

References (221)

1. Gill DM. Bacterial toxins: a table of lethal amounts. Microbiol Rev 1982; 46: 86-94.
2. Osborne SL, Latham CF, Wen PJ, Cavaignac S, Fanning J, Foran PG, et al. The Janus faces of botulium neurotoxin: sensational medicine and deadly biological weapon. J Neurosci Res 2007; 85: 1149-1158. (Pubitemid 46724359)
3. Truong DD, Jost WH. Botulinum toxin: clinical use. Parkinsonism Relat Disord 2006; 12: 331-355.
4. Schiavo G, Matteoli M, Montecucco C. Neurotoxins affecting neuroexocytosis. Physiol Rev 2000; 80: 717-766.
5. Eleopra R, Tugnoli V, Quatrale R, Rossetto O, Montecucco C. Mov Disord 2004; 19 Suppl 8: S53-S59.
6. Schulte-Mattler WJ. Use of botulinum toxin A in adult neurological disorders: efficacy, tolerability and safety. CNS Drugs 2008; 22: 725-738.
7. Sampaio C, Costa J, Ferreira JJ. Clinical comparability of marketed formulations of botulinum toxin. Mov Disord 2004; 19 (Suppl 8): S129-S136. (Pubitemid 38967522)
8. Eleopra R, Tugnoli V, Rossetto O, Montecucco C, De Grandis D. Botulinum neurotoxin serotype C: a novel effective botulinum toxin therapy in human. Neurosci Lett 1997; 12: 89-94. (Pubitemid 27122178)
9. Greene PE, Fahn S. Response to botulinum toxin F in seronegative botulinum toxin A-resistant patients. Mov Disord 1996; 11: 181-184. (Pubitemid 26082786)
10. Simpson LL. The origin, structure, and pharmacological activity of botulinum toxin. Pharmacol Rev 1981; 33: 155-188.
11. Brin MF. Botulinum toxin: chemistry, pharmacology, toxicity, and immunology. Muscle Nerve Suppl 1997; 6: S146-S169.
12. Wohlfarth K, Goschel H, Frevert J, Dengler R, Bigalke H. Botulinum A toxins: units versus units. Naunyn Schmiedebergs Arch Pharmacol 1997; 355: 335-340.
13. Mancini F, Zangaglia R, Cristina S, Sommaruga MG, Martignoni E, Nappi G, et al. Double-blind, placebo-controlled study to evaluate the efficacy and safety of botulinum toxin type A treatment of drooling in parkinsonism. Mov Disord 2003; 18: 685-688. (Pubitemid 36790285)
14. Frevert J. Xeomin is free from complexing proteins. Toxicon 2009; [Epub ahead of print].
15. Jost WH, Blumel J, Grafe S. Botulinum toxin type A free of complexing proteins (XEOMIN® in focal dystonia. Drugs 2007; 67: 669-683.
16. Odergren T, Hjaltason H, Kaakkola S, Solders G, Hanko J, Fehling C, et al. A double blind, randomised, parallel group study to investigate the dose equivalence of Dysport and Botox in the treatment of cervical dystonia. J Neurol Neurosurg Psychiatry 1998; 64: 6-12. (Pubitemid 28156530)
17. Sampaio C, Ferreira JJ, Simoes F, Rosas MJ, Magalhaes M, Correia AP, et al. DYSBOT: a single-blind, randomized parallel study to determine whether any differences can be detected in the efficacy and tolerability of two formulations of botulinum toxin type A-Dysport and Botox-assuming a ratio of 4: 1. Mov Disord 1997; 12: 1013-1018.
18. Ranoux D, Gury C, Fondarai J, Mas JL, Zuber M. Respective potencies of Botox and Dysport: a double blind, randomised, crossover study in cervical dystonia. J Neurol Neurosurg Psychiatry 2002; 72: 459-462. (Pubitemid 34289560)
19. Lu L, Atchabahian A, Mackinnon SE, Hunter DA. Nerve injection injury with botulinum toxin. Plast Reconstr Surg 1998; 101: 1875-1880. (Pubitemid 28262317)
20. Goschel H, Wohlfarth K, Frevert J, Dengler R, Bigalke H. Botulinum a toxins therapy: neutralizing and nonneutralizing antibodies-therapeutic consequences. Exp Neurol 1997;147: 96-102. (Pubitemid 27402446)
21. Voller B, Moraru E, Auff E, Beesch M, Poewe W, Wissel J, et al. Ninhydrin sweat test: a simple method for detecting antibodies neutralizing botulinum toxin type A. Mov Disord 2004; 19: 943-947. (Pubitemid 39199263)
22. Kessler KR, Benecke R. The EBD test-a clinical test for the detection of antibodies to botulinum toxin type A. Mov Disord 1997; 12: 95-99. (Pubitemid 27032886)
23. Herrmann J, Geth K, Mall V, Bigalke H, Schulte-Montig J, Linder M, et al. Clinical impact of antibody formation to botulinum toxin A in children. Ann Neurol 2004; 55: 732-735. (Pubitemid 38544335)
24. rd, Smith BP, Goodman A, Mulvaney T. Management of spasticity in cerebral palsy with botulinum-A toxin: report of a preliminary randomized, double-blind trial. J Pediatr Orthop 1994; 14: 299-303.
25. Rollnik JD, Wohlfarth K, Dengler R, Bigalke H. Neutralizing botulinum toxin type A antibodies: clinical observations in patients with cervical dystonia. Neurol Clin Neurophysiol 2001; 2001: 2-4. (Pubitemid 41548526)
26. Jankovic J, Schwartz K. Response and immunoresistance to botulinum toxin injections. Neurology 1995; 45: 1743-1746.
27. Dressler D. Clinical relevance of botulinum toxin antibodies. Nervearzt [German] 2008; 79: (Suppl 1): 36-40.
28. Costa J, Borges A, Espirito-Santo C, Ferreira J, Coelho M, Moore P, et al.. Botulinum toxin type A versus botulinum toxin type B for cervical dystonia. Cochrane Database Syst Rev 2005; CD004314.
29. Brans JW, de Boer IP, Aramideh M, Ongerboer de Visser BW, Speelman JD. Botulinum toxin in cervical dystonia: low dosage with electromyographic guidance. J Neurol 1995; 242: 529-534.
30. Krack P, Deuschl G, Benecke R, Ceballos-Baumann AO, Marion MH, Oertel WH, et al. Dose standardization of botulinum toxin. Mov Disord 1998; 13: 749-751.
31. Poewe W, Deuschl G, Nebe A, Feifel E, Wissel J, Benecke R, et al. What is the optimal dose of botulinum toxin A in the treatment of cervical dystonia? Results of a double blind, placebo controlled, dose ranging study using Dysport. German Dystonia Study Group. J Neurol Neurosurg Psychiatry 1998; 64: 13-17. (Pubitemid 28156531)
32. Van den Bergh P, Francart J, Mourin S, Kollmann P, Laterre EC. Five-year experience in the treatment of focal movement disorders with low-dose Dysport botulinum toxin. Muscle Nerve 1995; 18: 720-729.
33. Kruisdijk JJ, Koelman JH, Ongerboer de Visser BW, de Haan RJ, Speelman JD. Botulinum toxin for writer's cramp: a randomized, placebo-controlled trial and 1-year follow-up. J Neurol Neurosurg Psychiatry 2007; 78: 264-270.
34. Brashear A, Ambrosius WT, Eckert GJ, Siemers ER. Comparison of treatment of tardive dystonia and idiopathic cervical dystonia with botulinum toxin type A. Mov Disord 1998; 13: 158-161. (Pubitemid 28029869)
35. Kessler KR, Skutta M, Benecke R. Long-term treatment of cervical dystonia with botulinum toxin A: efficacy, safety, and antibody frequency. German Dystonia Study Group. J Neurol 1999; 246: 265-274. (Pubitemid 29229352)
36. Tsui JK, Eisen A, Mak E, Carruthers J, Scott A, Calne DB. A pilot study on the use of botulinum toxin in spasmodic torticollis. Can J Neurol Sci 1985; 12: 314-316. (Pubitemid 16198560)
37. Tsui JK, Eisen A, Stoessl AJ, Calne S, Calne DB. Double-blind study of botulinum toxin in spasmodic torticollis. Lancet 1986; 2: 245-247. (Pubitemid 16098897)
38. Stell R, Thompson PD, Marsden CD. Botulinum toxin in spasmodic torticollis. J Neurol Neurosurg Psychiatry 1988; 51: 920-923.
39. Brashear A, Lew MF, Dykstra DD, Comella CL, Factor SA, Rodnitzky RL, et al. Safety and efficacy of NeuroBloc (botulinum toxin type B) in type A-responsive cervical dystonia. Neurology 1999; 53: 1439-1446. (Pubitemid 29491934)
40. Brin MF, Lew MF, Adler CH, Comella CL, Factor SA, Jankovic J, et al. Safety and efficacy of NeuroBloc (botulinum toxin type B) in type-A resistant cervical dystonia. Neurology 1999; 53: 1431-1438. (Pubitemid 29491933)
41. Greene P, Kang U, Fahn S, Brin M, Moskowitz C, Flaster E. Double-blind, placebo-controlled trial of botulinum toxin injections for the treatment of spasmodic torticollis. Neurology 1990; 40: 1213-1218. (Pubitemid 20244977)
42. Brans JW, Lindeboom R, Snoek JW, Zwarts MJ, van Weerden TW, Brunt ER, et al. Botulinum toxin versus trihexyphenidyl in cervical dystonia: a prospective, randomized, double-blind controlled trial. Neurology 1996; 46: 1066-1072. (Pubitemid 26134654)
43. Lew MF, Adomato BT, Duane DD, Dykstra DD, Factor SA, Massey JM, et al. Botulinum toxin type B: a double-blind, placebo-controlled, safety and efficacy study in cervical dystonia. Neurology 1997; 49: 701-707.
44. Truong DD, Duane DD, Jankovic J, Singer C, Seeberger LC, Comella CL, et al. Efficacy and safety of botulinum type A toxin (Dysport) in cervical dystonia: results of the first US randomized, double-blind, placebo-controlled study. Mov Disord 2005; 20: 783-791. (Pubitemid 41227144)
45. Pappert EJ, Germanson T, Myobloc/Neurobloc European Cervical Dystonia Study Group. Mov Disord 2008; 23: 510-517.
46. Benecke R, Jost WH, Kanovsky P, Ruzicka E, Comes G, Grafe S. A new botulinum toxin type A free of complexing proteins for treatment of cervical dystonia. Neurology 2005; 64: 1949-1951. (Pubitemid 40800714)
47. Comella CL, Jankovic J, Shannon KM, Tsui J, Swenson M, Leurgans S, et al. Comparison of botulinum toxin serotypes A and B for the treatment of cervical dystonia. Neurology 2005; 65: 1423-1439. (Pubitemid 41552774)
48. Hallett M, Daroff RB. Blepharospasm: report of a workshop. Neurology 1996; 46: 1213-1218.
49. Jankovic J, Orman J. Botulinum A toxin for cranial-cervical dystonia: a double-blind, placebo-controlled study. Neurology 1987; 37: 616-623. (Pubitemid 17057937)
50. Nussgens Z, Roggenkamper P. Comparison of two botulinum-toxin preparations in the treatment of essential blepharospasm. Graefes Arch Clin Exp Ophthalmol 1997; 235: 197-199. (Pubitemid 27326086)
51. MacAndie K, Kemp E. Impact of quality of life of botulinum toxin treatments for essential blepharospasm. Orbit 2004; 23: 207-210. (Pubitemid 40007768)
52. Reimer J, Gilg K, Karow A, Esser J, Franke GH. Health-related quality of life in blepharospasm or hemifacial spasm. Acta Neurol Scand 2005; 111: 64-70.
53. Tucha O, Naumann M, Berg D, Alders GL, Lange KW. Quality of life in patients with blepharospasm. Acta Neurol Scand 2001; 103: 49-52.
54. Dutton JJ, Buckley EG. Long-term results and complications of botulinum A toxin in the treatment of blepharospasm. Ophthalmology 1988; 95: 1529-1534. (Pubitemid 18257212)
55. Price J, O'Day J. Efficacy and side effects of botulinum toxin treatment for blepharospasm and hemifacial spasm. Aust N Z J Ophthalmol 1994; 22: 255-260.
56. Price J, O'Day J. A comparative study of tear secretion in blepharospasm and hemifacial spasm patients treated with botulinum toxin. J Clin Neuroophthalmol 1993; 13: 67-71. (Pubitemid 23073101)
57. Blitzer A, Brin MF, Fahn S, Lange D, Lovelace RE. Botulinum toxin (BOTOX) for the treatment of "spastic dysphonia" as part of a trial of toxin injections for the treatment of other cranial dystonias. Laryngoscope 1986; 96: 1300-1301.
58. Blitzer A, Brin MF, Stewart CF. Botulinum toxin management of spasmodic dysphonia (laryngeal dystonia): a 12-year experience in more than 900 patients. Laryngoscope 1998; 108: 1435-1441. (Pubitemid 28465236)
59. Truong DD, Cullis PA, O'Brien CF, Koller M, Villegas TP, Wallace JD. BotB (botulinum toxin type B): evaluation of safety and tolerability in botulinum toxin type A-resistant cervical dystonia patients (preliminary study). Mov Disord 1997; 12: 772-775.
60. Boutsen F, Cannito MP, Taylor M, Bender B. Botox treatment in adductor spasmodic dysphonia: a meta-analysis. J Speech Lang Hear Res 2002; 45: 469-481. (Pubitemid 34596316)
61. Whurr R, Nye C, Lorch M. Meta-analysis of botulinum toxin treatment of spasmodic dysphonia: a review of 22 studies. Int J Lang Commun Disord 1998; 33 (Suppl): 327-329. (Pubitemid 28459128)
62. Brin MF, Blitzer A, Stewart C. Laryngeal dystonia (spasmodic dysphonia): observations of 901 patients and treatment with botulinum toxin. Adv Neurol 1998; 78: 237-252.
63. Truong DD. Botulinum toxin therapy. West J Med 1991; 155: 69-70.
64. Miller RH, Woodson GE, Jankovik J. Botulinum toxin injection of the vocal fold for spasmodic dysphonia. A preliminary report. Arch Otolaryngol Head Neck Surg 1987; 113: 603-605.
65. Ford CN, Bless DM, Lowery JD. Indirect laryngoscopic approach for injection of botulinum toxin in spasmodic dysphonia. Otolaryngol Head Neck Surg 1990; 103: 752-758.
66. Rhew K, Fiedler DA, Ludlow CL. Technique for injection of botulinum toxin through the flexible nasolaryngoscope. Otolaryngol Head Neck Surg 1994; 111: 787-794.
67. Green DC, Berke GS, Ward PH, Gerratt BR. Point-touch technique of botulinum toxin injection for the treatment of spasmodic dysphonia. Ann Otol Rhinol Laryngol 1992; 101: 883-887.
68. Bhattacharyya N, Tarsy D. Impact on quality of life of botulinum toxin treatments for spasmodic dysphonia and oromandibular dystonia. Arch Otolaryngol Head Neck Surg 2001; 127: 389-392. (Pubitemid 32299012)
69. Blitzer A, Brin MF, Greene PE, Fahn S. Botulinum toxin injection for the treatment of oromandibular dystonia. Ann Otol Rhinol Laryngol 1989; 98: 93-97. (Pubitemid 19057384)
70. Hermanowicz N, Truong DD. Treatment of oromandibular dystonia with botulinum toxin. Laryngoscope 1991; 101: 1216-1218.
71. Tan EK, Jankovic J. Botulinum toxin A in patients with oromandibular dystonia: long-term follow-up. Neurology 1999; 53: 2102-2107.
72. Jankovic J, Schwartz K, Donovan DT. Botulinum toxin treatment of cranial-cervical dystonia, spasmodic dysphonia, other focal dystonias and hemifacial spasm. J Neurol Neurosurg Psychiatry 1990; 53: 633-639. (Pubitemid 20253526)
73. Behari M, Singh KK, Seshadri S, Prasad K, Ahuja GK. Botulinum toxin A in blepharospasm and hemifacial spasm. J Assoc Physicians India 1994; 42: 205-208.
74. Berardelli A, Formica A, Mercuri B, Abbruzzese G, Agnoli A, Agostino R, et al. Botulinum toxin treatment in patients with focal dystonia and hemifacial spasm. A multicenter study of the Italian Movement Disorder Group. Ital J Neurol Sci 1993; 14: 361-367. (Pubitemid 23224351)
75. Laskawi R, Rohrbach S. [Oromandibular dystonia. Clinical forms, diagnosis and examples of therapy with botulinum toxin]. Laryngorhinootologie 2001; 80: 708-713.
76. Maurri S, Brogelli S, Alfieri G, Barontini F. Use of botulinum toxin in Meige's disease. Riv Neurol 1988; 58: 245-248.
77. Poungvarin N, Devahastin V, Chaisevikul R, Prayoonwiwat N, Viriyavejakul A. Botulinum A toxin treatment for blepharospasm and Meige syndrome: report of 100 patients. J Med Assoc Thai 1997; 80: 1-8. (Pubitemid 27207329)
78. Brin MF, Stewart C, Blitzer A, Diamond B. Laryngeal botulinum toxin injections for disabling stuttering in adults. Neurology 1994; 44: 2262-2266. (Pubitemid 24382721)
79. Karp BI, Cole RA, Cohen LG, Grill S, Lou JS, Hallett M. Long-term botulinum toxin treatment of focal hand dystonia. Neurology 1994; 44: 70-76. (Pubitemid 24029432)
80. Karp BI. Botulinum toxin treatment of occupational and focal hand dystonia. Mov Disord 2004; 19 (Suppl 8): S116-S119. (Pubitemid 38967520)
81. Lees AJ, Turjanski N, Rivest J, Whurr R, Lorch M, Brookes G. Treatment of cervical dystonia hand spasms and laryngeal dystonia with botulinum toxin. J Neurol 1992; 234: 1-4.
82. Poungvarin N. Writer's cramp: the experience with botulinum toxin injections in 25 patients. J Med Assoc Thai 1991; 74: 239-247.
83. Turjanski N, Pirtosek Z, Quirk J, Anderson TJ, Rivest J, Marsden CD, et al. Botulinum toxin in the treatment of writer's cramp. Clin Neuropharmacol 1996; 19: 314-320. (Pubitemid 26250114)
84. Hsiung GY, Das SK, Ranawaya R, Lafontaine AL, Suchowersky O. Long-term efficacy of botulinum toxin A in treatment of various movement disorders over a 10-year period. Mov Disord 2002; 17: 1288-1293. (Pubitemid 36041344)
85. Djebbari R, du Montcel ST, Sangla S, Vidal JS, Gallouedec G, Vidailhet M. Factors predicting improvement in motor disability in writer's cramp treated with botulinum toxin. J Neurol Neurosurg Psychiatry 2004; 75: 1688-1691.
86. Tsui JK, Bhatt M, Calne S, Calne DB. Botulinum toxin in the treatment of writer's cramp: a double-blind study. Neurology 1993; 43: 183-185. (Pubitemid 23035378)
87. Schuele S, Jabusch HC, Lederman RJ, Altenmuller E. Botulinum toxin injections in the treatment of musician's dystonia. Neurology 2005; 64: 341-343.
88. Schuele S, Lederman RJ. Long-term outcome of focal dystonia in string instrumentalists. Mov Disord 2004; 19: 43-48. (Pubitemid 38559619)
89. Quirk JA, Sheean GL, Marsden CD, Lees AJ. Treatment of nonoccupational limb and trunk dystonia with botulinum toxin. Mov Disord 1996; 11: 377-383. (Pubitemid 26235774)
90. Ghika J, Nater B, Henderson J, Bogousslavsky J, Regli F. Delayed segmental axial dystonia of the trunk on standing after lumbar disk operation. J Neurol Sci 1997; 152: 193-197. (Pubitemid 27509188)
91. Mezaki T, Kaji R, Hamano T, Nagamine T, Shibasaki H, Shimizu T, et al. Optimisation of botulinum treatment for cervical and axial dystonias: experience with a Japanese type A toxin. J Neurol Neurosurg Psychiatry 1994; 57: 1535-1537.
92. Comella CL, Shannon KM, Jaglin J. Extensor truncal dystonia: successful treatment with botulinum toxin injections. Mov Disord 1998; 13: 552-555. (Pubitemid 28221514)
93. Fahn S. Tardive dyskinesias. Edinburgh: Churchill Livingstone 1984.
94. Burke RE, Fahn S, Jankovic J, Marsden CD, Lang AE, Gollomp S, et al. Tardive dystonia: late-onset and persistent dystonia caused by antipsychotic drugs. Neurology 1982; 32: 1335-1346. (Pubitemid 13203738)
95. Kang UJ, Burke RE, Fahn S. Tardive dystonia. Adv Neurol 1988; 50: 415-429.
96. Truong DD, Hermanowicz N, Rontal M. Botulinum toxin in treatment of tardive dyskinetic syndrome. J Clin Psychopharmacol 1990; 10: 438-439.
97. Burke RE. Idiopathic torsion dystonia. Mov Disord 1992; 7: 387-388.
98. Jankovic J, Leder S, Warner D, Schwartz K. Cervical dystonia: clinical findings and associated movement disorders. Neurology 1991; 41: 1088-1091.
99. Stip E, Faughnan M, Desjardin I, Labrecque R. Botulinum toxin in a case of severe tardive dyskinesia mixed with dystonia. Br J Psychiatry 1992; 161: 867-868.
100. Kaufman DM. Use of botulinum toxin injections for spasmodic torticollis of tardive dystonia. J Neuropsychiatry Clin Neurosci 1994; 6: 50-53. (Pubitemid 24047441)
101. Yasufuku-Takano J, Sakurai M, Kanazawa I, Nagaoka M. Successful treatment of intractable tardive dyskinesia with botulinum toxin. J Neurol Neurosurg Psychiatry 1995; 58: 511-512.
102. Shulman LM, Singer C, Weiner WJ. Improvement of both tardive dystonia and akathisia after botulinum toxin injection. Neurology 1996; 46: 844-845. (Pubitemid 26099665)
103. Tarsy D, Kaufman D, Sethi KD, Rivner MH, Molho E, Factor S. An open-label study of botulinum toxin A for treatment of tardive dystonia. Clin Neuropharmacol 1997; 20: 90-93. (Pubitemid 27098361)
104. Kanovsky P, Streitova H, Bares M, Hortova H. Treatment of facial and orolinguomandibular tardive dystonia by botulinum toxin A: evidence of a long-lasting effect. Mov Disord 1999; 14: 886-888. (Pubitemid 29509644)
105. Scott BL, Jankovic J, Donovan DT. Botulinum toxin injection into vocal cord in the treatment of malignant coprolalia associated with Tourette's syndrome. Mov Disord 1996; 11: 431. (Pubitemid 26235782)
106. Trimble MR, Whurr R, Brookes G, Robertson MM. Vocal tics in Gilles de la Tourette syndrome treated with botulinum toxin injections. Mov Disord 1998; 13: 617-619. (Pubitemid 28221532)
107. Salloway S, Stewart CF, Israeli L, Morales X, Rasumssen S, Blitzer A, et al. Botulinum toxin for refractory vocal tics. Mov Disord 1996; 11: 746-748. (Pubitemid 26381951)
108. Krauss JK, Jankovic J. Severe motor tics causing cervical myelopathy in Tourette's syndrome. Mov Disord 1996; 11: 563-566. (Pubitemid 26306083)
109. Jankovic J. Botulinum toxin in the treatment of dystonic tics. Mov Disord 1994; 9: 347-349. (Pubitemid 24150125)
110. Kwak CH, Hanna PA, Jankovic J. Botulinum toxin in the treatment of tics. Arch Neurol 2000; 57: 1190-1193.
111. Pal PK, Samii A, Schulzer M, Mak E, Tsui JK. Head tremor in cervical dystonia. Can J Neurol Sci 2000; 27: 137-142.
112. Wissel J, Masuhr F, Schelosky L, Ebersbach G, Poewe W. Quantitative assessment of botulinum toxin treatment in 43 patients with head tremor. Mov Disord 1997; 12: 722-726. (Pubitemid 27406268)
113. Jankovic J, Schwartz K. Botulinum toxin treatment of tremors. Neurology 1991; 41: 1185-1188.
114. Henderson JM, Ghika JA, Van Melle G, Haller E, Einstein R. Botulinum toxin A in non-dystonic tremors. Eur Neurol 1996; 36: 29-35.
115. Jankovic J, Schwartz K, Clemence W, Aswad A, Mordaunt J. A randomized, double-blind, placebo-controlled study to evaluate botulinum toxin type A in essential hand tremor. Mov Disord 1996; 11: 250-256. (Pubitemid 26138822)
116. Trosch RM, Pullman SL. Botulinum toxin A injections for the treatment of hand tremors. Mov Disord 1994; 9: 601-609. (Pubitemid 24343277)
117. Brin MF, Lyons KE, Doucette J, Adler CH, Caviness JN, Comella CL, et al. A randomized, double masked, controlled trial of botulinum toxin type A in essential hand tremor. Neurology 2001; 56: 1523-1528. (Pubitemid 32532264)
118. Deuschl G, Lohle E, Heinen F, Lucking C. Ear click in palatal tremor: its origin and treatment with botulinum toxin. Neurology 1991; 41: 1677-1679.
119. Grazko MA, Polo KB, Jabbari B. Botulinum toxin A for spasticity, muscle spasms, and rigidity. Neurology 1995; 45: 712-717.
120. Baker R, Jasinski M, Maciag-Tymecka I, Michalowska-Mrozek J, Bonikowski M, Carr L, et al. Botulinum toxin treatment of spasticity in diplegic cerebral palsy: a randomized, double-blind, placebo-controlled, dose-ranging study. Dev Med Child Neurol 2002; 44: 666-675. (Pubitemid 35230027)
121. Brashear A, Gordon MF, Elovic E, Kassicieh VD, Marciniak C, Do M, et al. Intramuscular injection of botulinum toxin for the treatment of wrist and finger spasticity after a stroke. N Engl J Med 2002; 347: 395-400. (Pubitemid 34851831)
122. Bakheit AM, Thilmann AF, Ward AB, Poewe W, Wissel J, Muller J, et al. A randomized, double-blind, placebo-controlled, dose-ranging study to compare the efficacy and safety of three doses of botulinum toxin type A (Dysport) with placebo in upper limb spasticity after stroke. Stroke 2000; 31: 2402-2406. (Pubitemid 30740550)
123. Bakheit AM, Pittock S, Moore AP, Wurker M, Otto S, Erbguth F, et al. A randomized, double-blind, placebo-controlled study of the efficacy and safety of botulinum toxin type A in upper limb spasticity in patients with stroke. Eur J Neurol 2001; 8: 559-565. (Pubitemid 35015221)
124. Burbaud P, Wiart L, Dubos JL, Gaujard E, Debelleix X, Joseph PA, et al. A randomised, double blind, placebo controlled trial of botulinum toxin in the treatment of spastic foot in hemiparetic patients. J Neurol Neurosurg Psychiatry 1996; 61: 265-269. (Pubitemid 26293721)
125. Childers MK, Brashear A, Jozefczyk P, Reding M, Alexander D, Good D, et al. Dose-dependent response to intramuscular botulinum toxin type A for upper-limb spasticity in patients after a stroke. Arch Phys Med Rehabil 2004; 85: 1063-1069. (Pubitemid 38962361)
126. Hyman N, Barnes M, Bhakta B, Cozens A, Bakheit M, Kreczy-Kleedorfer B, et al. Botulinum toxin (Dysport) treatment of hip adductor spasticity in multiple sclerosis: a prospective, randomised, double blind, placebo controlled, dose ranging study. J Neurol Neurosurg Psychiatry 2000; 68: 707-712. (Pubitemid 30265269)
127. Mall V, Heinen F, Siebel A, Bertram C, Hafkemeyer U, Wissel J, et al. Treatment of adductor spasticity with BTX-A in children with CP: a randomized, double-blind, placebo-controlled study. Dev Med Child Neurol 2006; 48: 10-13. (Pubitemid 43124451)
128. Mancini F, Sandrini G, Moglia A, Nappi G, Pacchetti C. A randomised, double-blind, dose-ranging study to evaluate efficacy and safety of three doses of botulinum toxin type A (Botox) for the treatment of spastic foot. Neurol Sci 2005; 26: 26-31. (Pubitemid 40723938)
129. Simpson DM, Alexander DN, O'Brien CF, Tagliati M, Aswad AS, Leon JM, et al. Botulinum toxin type A in the treatment of upper extremity spasticity: a randomized, double-blind, placebo-controlled trial. Neurology 1996; 46: 1306-1310. (Pubitemid 26159292)
130. Smith SJ, Ellis E, White S, Moore AP. A double-blind placebo-controlled study of botulinum toxin in upper limb spasticity after stroke or head injury. Clin Rehabil 2000; 14: 5-13. (Pubitemid 30072216)
131. Snow BJ, Tsui JK, Bhatt MH, Varelas M, Hashimoto SA, Calne DB. Treatment of spasticity with botulinum toxin: a double-blind study. Ann Neurol 1990; 28: 512-515. (Pubitemid 20359157)
132. Pittock SJ, Moore AP, Hadiman O, Ehler E, Kovac M, Bojakowski J, et al. A double-blind randomised placebo-controlled evaluation of three doses of botulinum toxin type A (Dysport) in the treatment of spastic equinovarus deformity after stroke. Cerebrovasc Dis 2003; 15: 289-300. (Pubitemid 36438734)
133. Verplancke D, Snape S, Salisbury CF, Jones PW, Ward AB. A randomized controlled trial of botulinum toxin on lower limb spasticity following acute acquired severe brain injury. Clin Rehabil 2005; 19: 117-125. (Pubitemid 40309182)
134. Houltram J, Noble I, Boyd RN, Corry I, Flett P, Graham HK. Botulinum toxin type A in the management of equinus in children with cerebral palsy: an evidence-based economic evaluation. Eur J Neurol 2001; 8 (Suppl 5): 194-202. (Pubitemid 33757705)
135. Ward A, Roberts G, Warner J, Gillard S. Cost-effectiveness of botulinum toxin type a in the treatment of post-stroke spasticity. J Rehabil Med 2005; 37: 252-257. (Pubitemid 41025335)
136. Scott AB. Injection treatment of endocrine orbital myopathy. Doc Ophthalmol 1984; 58: 141-145.
137. Quah BL, Ling YL, Cheong PY, Balakrishnan V. A review of 5 years' experience in the use of botulinium toxin A in the treatment of sixth cranial nerve palsy at the Singapore National Eye Centre. Singapore Med J 1999; 40: 405-409. (Pubitemid 29382597)
138. Kikkawa DO, Cruz RC Jr, Christian WK, Rikkers S, Weinreb RN, Levi L, et al. Botulinum A toxin injection for restrictive myopathy of thyroid-related orbitopathy: effects on intraocular pressure. Am J Ophthalmol 2003; 135: 427-431. (Pubitemid 36315950)
139. Ellis MF, Daniell M. An evaluation of the safety and efficacy of botulinum toxin type A (BOTOX) when used to produce a protective ptosis. Clin Experiment Ophthalmol 2001; 29: 394-399. (Pubitemid 34036741)
140. Boroojerdi B, Ferbert A, Schwarz M, Herath H, Noth J. Botulinum toxin treatment of synkinesia and hyperlacrimation after facial palsy. J Neurol Neurosurg Psychiatry 1998; 65: 111-114. (Pubitemid 28302367)
141. Keegan DJ, Geerling G, Lee JP, Blake G, Collin JR, Plant GT. Botulinum toxin treatment for hyperlacrimation secondary to aberrant regenerated seventh nerve palsy or salivary gland transplantation. Br J Ophthalmol 2002; 86: 43-46. (Pubitemid 34074883)
142. Montoya FJ, Riddell CE, Caesar R, Hague S. Treatment of gustatory hyperlacrimation (crocodile tears) with injection of botulinum toxin into the lacrimal gland. Eye 2002; 16: 705-709. (Pubitemid 35460547)
143. Riemann R, Pfennigsdorf S, Riemann E, Naumann M. Successful treatment of crocodile tears by injection of botulinum toxin into the lacrimal gland: a case report. Ophthalmology 1999; 106: 2322-2324. (Pubitemid 30191446)
144. Hofmann RJ. Treatment of Frey's syndrome (gustatory sweating) and 'crocodile tears' (gustatory epiphora) with purified botulinum toxin. Ophthal Plast Reconstr Surg 2000; 16: 289-291.
145. Van Zandijcke M, Marchau MM. Treatment of bruxism with botulinum toxin injections. J Neurol Neurosurg Psychiatry 1990; 53: 530. (Pubitemid 20189593)
146. Tan EK, Jankovic J. Treating severe bruxism with botulinum toxin. J Am Dent Assoc 2000; 131: 211-216.
147. Cheshire WP, Freeman R. Disorders of sweating. Semin Neurol 2003; 23: 399-406.
148. Swartling C, Naver H, Pihl-Lundin I, Hagforsen E, Vahlquist A. Sweat gland morphology and periglandular innervation in essential palmar hyperhidrosis before and after treatment with intradermal botulinum toxin. J Am Acad Dermatol 2004; 51: 739-745. (Pubitemid 39516888)
149. Naumann M, Lowe NJ. Botulinum toxin type A in treatment of bilateral primary axillary hyperhidrosis: randomised, parallel group, double blind, placebo controlled trial. BMJ 2001; 323: 596-599. (Pubitemid 32846124)
150. Naumann MK, Hamm H, Lowe NJ. Effect of botulinum toxin type A on quality of life measures in patients with excessive axillary sweating: a randomized controlled trial. Br J Dermatol 2002; 147: 1218-1226. (Pubitemid 36963031)
151. Schnider P, Binder M, Auff E, Kittler H, Berger T, Wolff K. Double-blind trial of botulinum A toxin for the treatment of focal hyperhidrosis of the palms. Br J Dermatol 1997; 136: 548-552. (Pubitemid 27160329)
152. Naumann M, Hofmann U, Bergmann I, Hamm H, Toyka KV, Reiners K. Focal hyperhidrosis: effective treatment with intracutaneous botulinum toxin. Arch Dermatol 1998; 134: 301-304. (Pubitemid 28141617)
153. Naumann M, Bergmann I, Hofmann U, Hamm H, Reiners K. Botulinum toxin for focal hyperhidrosis: technical considerations and improvements in application. Br J Dermatol 1998; 139: 1123-1124. (Pubitemid 29010568)
154. Odderson IR. Axillary hyperhidrosis: treatment with botulinum toxin A. Arch Phys Med Rehabil 1998; 79: 350-352. (Pubitemid 28207128)
155. Schnider P, Bider M, Kittler H, Birner P, Starkel D, Wolff K, et al. A randomized, double-blind, placebo-controlled trial of botulinum A toxin for severe axillary hyperhidrosis. Br J Dermatol 1999; 140: 677-680. (Pubitemid 29191388)
156. Shelley WB, Talanin NY, Shelley ED. Botulinum toxin therapy for palmar hyperhidrosis. J Am Acad Dermatol 1998; 38: 227-229.
157. Naumann M, Jost WH, Toyka KV. Botulinum toxin in the treatment of neurological disorders of the autonomic nervous system. Arch Neurol 1999; 56: 914-916. (Pubitemid 29374807)
158. Glogau RG. Botulinum A neurotoxin for axillary hyperhidrosis. No sweat Botox. Dermatol Surg 1998; 24: 817-819.
159. Naver H, Swartling C, Aquilonius SM. Treatment of focal hyperhidrosis with botulinum toxin type A. Brief overview of methodology and 2 years' experience. Eur J Neurol 1999; 6: S117-S120. (Pubitemid 30029051)
160. Naver H, Swartling C, Aquilonius SM. Palmar and axillary hyperhidrosis treated with botulinum toxin: one-year clinical follow-up. Eur J Neurol 2000; 7: 55-62. (Pubitemid 32268736)
161. Heckmann M, Breit S, Ceballos-Baumann A, Schaller M, Plewig G. Side-controlled intradermal injection of botulinum toxin A in recalcitrant axillary hyperhidrosis. J Am Acad Dermatol 1999; 41: 987-990.
162. Heckmann M, Ceballos-Baumann AO, Plewig G. Botulinum toxin A for axillary hyperhidrosis (excessive sweating). N Engl J Med 2001; 344: 488-493. (Pubitemid 32164900)
163. Solomon BA, Hayman R. Botulinum toxin type A therapy for palmar and digital hyperhidrosis. J Am Acad Dermatol 2000; 42: 1026-1029. (Pubitemid 30368673)
164. Karamfilov T, Konrad H, Karte K, Wollina U. Lower relapse rate of botulinum toxin A therapy for axillary hyperhidrosis by dose increase. Arch Dermatol 2000; 136: 487-490. (Pubitemid 30212960)
165. Swartling C, Naver H, Lindberg M. Botulinum A toxin improves life quality in severe primary focal hyperhidrosis. Eur J Neurol 2001 May; 8: 247-252. (Pubitemid 32476623)
166. Heckmann M, Plewig G, Hyperhidrosis Study Group. Low-dose efficacy of botulinum toxin A for axillary hyperhidrosis: a randomized, side-by-side, open-label study. Arch Dermatol 2005; 141: 1255-1299. (Pubitemid 41498923)
167. Krogstad AL, Skymne A, Pegenius G, Elam M, Wallin BG. No compensatory sweating after botulinum toxin treatment of palmar hyperhidrosis. Br J Dermatol 2005; 152: 329-333. (Pubitemid 40343606)
168. Dressler D, Adib Saberi F, Benecke R. Botulinum toxin type B for treatment of axillar hyperhidrosis. J Neurol 2002; 249: 1729-1732. (Pubitemid 36269268)
169. Dressler D, Benecke R. Autonomic side effects of botulinum toxin type B treatment of cervical dystonia and hyperhidrosis. Eur Neurol 2003; 49: 34-38. (Pubitemid 35477966)
170. Carruthers JA, Lowe NJ, Menter MA, Gibson J, Nordquist M, Mordaunt J, et al. A multicenter, double-blind, randomized, placebo-controlled study of the efficacy and safety of botulinum toxin type A in the treatment of glabellar lines. J Am Acad Dermatol 2002; 46: 840-849.
171. Carruthers JD, Carruthers JA. Treatment of glabellar frown lines with C. botulinum-A exotoxin. J Dermatol Surg Oncol 1992; 18: 17-21.
172. Drobik C, Laskawi R. Frey's syndrome: treatment with botulinum toxin. Acta Otolaryngol 1995; 115(3): 459-461.
173. Laskawi R, Drobik C, Schonebeck C. Up-to-date report of botulinum toxin type A treatment in patients with gustatory sweating (Frey's syndrome). Laryngoscope 1998; 108: 381-384. (Pubitemid 28136646)
174. Naumann M, Zellner M, Toyka KV, Reiners K. Treatment of gustatory sweating with botulinum toxin. Ann Neurol 1997; 42: 973-975. (Pubitemid 28008428)
175. Bergmann I, Dauphin M, Naumann M, Flachenecker P, Mullges W, Koltzenburg M, et al. Selective degeneration of sudomotor fibers in Ross syndrome and successful treatment of compensatory hyperhidrosis with botulinum toxin. Muscle Nerve 1998; 21: 1790-1793. (Pubitemid 28545715)
176. Schurch B, Schmid DM, Stohrer M. Treatment of neurogenic incontinence with botulinum toxin A. N Engl J Med 2000; 342: 665. (Pubitemid 30118430)
177. Reitz A, Stohrer M, Kramer G, Del Popolo G, Chartier-Kastler E, et al. European experience of 200 cases treated with botulinum-A toxin injections into the detrusor muscle for urinary incontinence due to neurogenic detrusor overactivity. Eur Urol 2004; 4(5): 510-515 (Pubitemid 38376219)
178. Kuo HC. Urodynamic evidence of effectiveness of botulinum A toxin injection in treatment of detrusor overactivity refractory to anticholinergic agents. Urology 2004; 63: 868-872.
179. Kuo HC. Therapeutic effects of suburothelial injection of botulinum a toxin for neurogenic detrusor overactivity due to chronic cerebrovascular accident and spinal cord lesions. Urology 2006; 67: 232-236.
180. Grosse J, Kramer G, Stohrer M. Success of repeat detrusor injections of botulinum a toxin in patients with severe neurogenic detrusor overactivity and incontinence. Eur Urol 2005; 47: 653-659. (Pubitemid 40521915)
181. Dykstra DD, Sidi AA, Scott AB, Pagel JM, Goldish GD. Effects of botulinum A toxin on detrusor-sphincter dyssynergia in spinal cord injury patients. J Urol 1988; 139: 919-922. (Pubitemid 18124789)
182. Petit H, Wiart L, Gaujard E, Le Breton F, Ferrriere JM, Laguey A, et al. Botulinum A toxin treatment for detrusor-sphincter dyssynergia in spinal cord disease. Spinal Cord 1998; 36: 91-94. (Pubitemid 28059487)
183. Schurch B, Hauri D, Rodic B, Curt A, Meyer M, Rossier AB. Botulinum-A toxin as a treatment of detrusor-sphincter dyssynergia: a prospective study in 24 spinal cord injury patients. J Urol 1996; 155: 1023-1029. (Pubitemid 26052703)
184. Schurch B, Hodler J, Rodic B. Botulinum A toxin as a treatment of detrusor-sphincter dyssynergia in patients with spinal cord injury: MRI controlled transperineal injections. J Neurol Neurosurg Psychiatry. 1997; 63: 474-476. (Pubitemid 27423554)
185. Jost WH, Naumann M. Botulinum toxin in neuro-urological disorders. Mov Disord 2004; 19 (Suppl 8): S142-S145.
186. Brin MF, Vapnek JM. Treatment of vaginismus with botulinum toxin injections. Lancet 1997; 349: 252-253. (Pubitemid 27050996)
187. Ghazizadeh S, Nikzad M. Botulinum toxin in the treatment of refractory vaginismus. Obstet Gynecol 2004; 104: 922-925. (Pubitemid 40458751)
188. Pasricha PJ, Ravich WJ, Hendrix TR, Sostre S, Jones B, Kalloo AN. Intrasphincteric botulinum toxin for the treatment of achalasia. N Engl J Med 1995; 332: 774-778.
189. Annese V, Basciani M, Perri F, Lombardi G, Frusciante V, Simone P, et al. Controlled trial of botulinum toxin injection versus placebo and pneumatic dilation in achalasia. Gastroenterology 1996; 111: 1418-1424. (Pubitemid 26404204)
190. Muehldorfer SM, Schneider TH, Hochberger J, Martus P, Hahn EG, Ell C. Esophageal achalasia: intrasphincteric injection of botulinum toxin A versus balloon dilation. Endoscopy 1999; 31: 517-521. (Pubitemid 29457227)
191. Ghoshal UC, Chaudhuri S, Pal BB, Dhar K, Ray G, Banerjee PK. Randomized controlled trial of intrasphincteric botulinum toxin A injection versus balloon dilatation in treatment of achalasia cardia. Dis Esophagus 2001; 14: 227-231. (Pubitemid 34170812)
192. Jost WH. Ten years' experience with botulin toxin in anal fissure. Int J Colorectal Dis 2002; 17: 298-302.
193. Ishikawa H, Mitsui Y, Yoshitomi T, Mashimo K, Aoki S, Mukuno K, et al. [Presynaptic effects of botulinum toxin type A on the neuronally evoked response of albino and pigmented rabbit iris sphincter and dilator muscles]. Nippon Ganka Gakkai Zasshi 2001; 105: 218-222.
194. Welch MJ, Purkiss JR, Foster KA. Sensitivity of embryonic rat dorsal root ganglia neurons to Clostridium botulinum neurotoxins. Toxicon 2000; 38: 245-258.
195. Sala C, Andreose JS, Fumagalli G, Lomo T. Calcitonin gene-related peptide: possible role in formation and maintenance of neuromuscular junctions. J Neurosci 1995; 15: 520-528.
196. Suzuki N, Hardebo JE, Kahrstrom J, Owman C. Neuropeptide Y co-exists with vasoactive intestinal polypeptide and acetylcholine in parasympathetic cerebrovascular nerves originating in the sphenopalatine, otic, and internal carotid ganglia of the rat. Neuroscience 1990; 36: 507-519. (Pubitemid 20247114)
197. Puffer EB, Lomneth RB, Sarkar HK, Singh BR. Differential roles of developmentally distinct SNAP-25 isoforms in the neurotransmitter release process. Biochemistry 2001; 40: 9374-9378
198. Yuan RY, Sheu JJ, Yu JM, Chen WT, Tseng IJ, Change HH, Hu CJ. Botulinum toxin for diabetic neuropathic pain: a randomized double-blind crossover trial. Neurology 2009; 72: 1473-1478.
199. Ellies M, Laskawi R, Rohrbach-Volland S, Arglebe C. Up-to-date report of botulinum toxin therapy in patients with drooling caused by different etiologies. J Oral Maxillofac Surg 2003; 61: 454-457. (Pubitemid 36396973)
200. Giess R, Naumann M, Werner E, Riemann R, Beck M, Puls I, et al. Injections of botulinum toxin A into the salivary glands improve sialorrhoea in amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiatry 2000; 69: 121-123. (Pubitemid 30410428)
201. Mancini F, Zangaglia R, Cristina S, Sommaruga MG, Martignoni E, Nappi G, et al. Double-blind, placebo-controlled study to evaluate the efficacy and safety of botulinum toxin type A in the treatment of drooling in parkinsonism. Mov Disord 2003; 18: 685-688. (Pubitemid 36790285)
202. Lagalla G, Millevolte M, Capecci M, Provinciali L, Ceravolo MG. Botulinum toxin type A for drooling in Parkinson's disease: A double-blind, randomized, placebo-controlled study. Mov Disord 2006; 21: 704-707. (Pubitemid 43792756)
203. Racette BA, Good L, Sagitto S, Perlmutter JS. Botulinum toxin B reduces sialorrhea in parkinsonism. Mov Disord 2003; 18: 1059-1061 (Pubitemid 37185218)
204. Ondo WG, Hunter C, Moore W. A double-blind placebo-controlled trial of botulinum toxin B for sialorrhea in Parkinson's disease. Neurology 2004; 62: 37-40. (Pubitemid 38082867)
205. Suskind DL, Tilton A. Clinical study of botulinum-A toxin in the treatment of sialorrhea in children with cerebral palsy. Laryngoscope 2002; 112: 73-81. (Pubitemid 34037741)
206. Jost WH. Treatment of drooling in Parkinson's disease with botulinum toxin. Mov Disord 1999; 14: 1057.
207. Tan EK, Lo YL, Seah A, Auchus AP. Recurrent jaw dislocation after botulinum toxin treatment for sialorrhoea in amyotrophic lateral sclerosis. J Neurol Sci 2001; 190: 95-97. (Pubitemid 33713028)
208. Winterholler MG, Erbguth FJ, Wolf S, Kat S. Botulinum toxin for the treatment of sialorrhoea in ALS: serious side effects of a transductal approach. J Neurol Neurosurg Psychiatry 2001; 70: 417-418. (Pubitemid 32250917)
209. Cadeddu F, Bentivoglio AR, Brandara F, Marniga G, Brisinda G, Maria G. Outlet type constipation in Parkinson's disease: results of botulinum toxin treatment. Aliment Pharmacol Ther. 2005; 22: 997-1003. (Pubitemid 41634882)
210. Giladi N, Gurevich T, Shabtai H, Paleacu D, Simon ES. The effect of botulinum toxin injections to the calf muscles on freezing of gait in parkinsonism: a pilot study. J Neurol 2001; 248: 572-576. (Pubitemid 32695798)
211. Fernandez HH, Lannon MC, Trieschmann ME, Friedman JH. Botulinum toxin type B for gait freezing in Parkinson's disease. Med Sci Monit 2004; 10: CR28204.
212. Wieler M, Camicioli R, Jones CA, Martin WR. Botulinum toxin injections do not improve freezing of gait in Parkinson disease. Neurology 2005 Aug 23;65: 626-628. (Pubitemid 41170731)
213. Shah SN, Hornyak J, Urquhart AG. Flexion contracture after total knee arthroplasty in a patient with Parkinson's disease: successful treatment with botulinum toxin type A. J Arthroplasty 2005; 20: 1078-1080. (Pubitemid 41820998)
214. Singer C, Papapetropoulos S. Lower limb post-immobilization dystonia in Parkinson's disease. J Neurol Sci 2005; 239: 111-114. (Pubitemid 41617423)
215. Guo Y, Shin K. Unique use of botulinum toxin to decrease adductor tone and allow surgical excision of vulvar carcinoma. Int J Gynecol Cancer 2004; 14: 100-103. (Pubitemid 38280630)
216. Cordivari C, Misra VP, Catania S, Lees AJ. Treatment of dystonic clenched fist with botulinum toxin. Mov Disord 2001; 16: 907-913. (Pubitemid 36041193)
217. Pacchetti C, Albani G, Martignoni E, Godi L, Alfonsi E, Nappi G. "Off" painful dystonia in Parkinson's disease treated with botulinum toxin. Mov Disord 1995; 10: 333-336.
218. Azher SN, Jankovic J. Camptocormia: pathogenesis, classification, and response to therapy. Neurology 2005; 65: 355-359. (Pubitemid 41099795)
219. Baker D, Pryce G. The endocannabinoid system and multiple sclerosis. Curr Pharm Des 2008; 14(23): 2326-2336
220. Di Filippo M, Picconi B, Tozzi A, Ghiglieri V, Rossi A, Calabresi P. The endocannabinoid system in Parkinson's disease. Curr Pharm Des 2008; 14(23): 2337-2347
221. Simola N, Morelli M, Pinna A. Adenosine A2A receptor antagonists and Parkinson's disease: state of the art and future directions. Curr Pharm Des 2008; 14(15): 1475-1489 (Pubitemid 351997813)